Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium

British Journal of Pharmacology

Volumn 130, Issue 5, 2000, Pages 1131-1139

  Maack, C ^a   Cremers, B ^a   Flesch, M ^a   Hoper A ^a   Sudkamp M ^a   Bohm M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Heart failure; Human myocardium; Intrinsic activity; Inverse agonism; adrenoceptor antagonists

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ADENYLATE CYCLASE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BUCINDOLOL; CARVEDILOL; CYANOPINDOLOL I 125; FORSKOLIN; GUANINE NUCLEOTIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOPRENALINE; METOPROLOL; RADIOLIGAND;

ARTICLE; CONTROLLED STUDY; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE; HUMAN; HUMAN TISSUE; INOTROPISM; LIGAND BINDING; PRIORITY JOURNAL;

EID: 0033936705     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703400     Document Type: Article

References (34)

1. BENOVIC, J.L., STANISZEWSKI, C., MAYOR, F., CARON, M.G. & LEFKOWITZ, R.J. (1988). β-Adrenergic receptor kinase. J. Biol. Chem., 263, 3893-3897.
2. BEST STEERING COMMITTEE. (1995). Design of the Beta-blocker Evaluation Survival Trial (BEST). Am J Cardiol., 75, 1220-1223.
3. BÖHM, M., ETTELBRÜCK, S., FLESCH, M., VAN GIELST, W.H., KNORR, A., MAACK, C., PINTO, Y.M., PAUL, M., TEISMAN, A.C.H. & ZOLK, O. (1998). β-Adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. Cardiovasc. Res., 40, 146-155.
4. BÖHM, M., GIERSCHIK, P., JAKOBS, K.-H., PIESKE, B., SCHNABEL, P., UNGERER, M. & ERDMANN, E. (1990a). Increase of Giα in human hearts with dilated but not ischemic cardiomyopathy. Circulation, 82, 1249-1265.
5. BÖHM, M., MITTMANN, C., SCHWINGER, R.H.G. & ERDMANN, E. (1990b). Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity. Am. Heart J., 120, 1381-1392.
6. 2-adrenoceptor. Nature, 374, 272-276.
7. BRISTOW, M.R. (2000). β-Adrenergic receptor blockade in chronic heart failure. Circulation, 101, 558-569.
8. BRISTOW, M.R., GINSBURG, R., MINOBE, W., CUBICIOTTI, R.S., SAGEMAN, W.S., LURIE, K., BILLINGHAM, M.E., HARRISON, D.E. & STINSON, E.B. (1982). Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N. Engl. J. Med., 307, 205-211.
9. BRISTOW, M .R., LARRABEE, P., MINOBE, W., RODEN, R., SKERL, L., KLEIN, J., HANDWERGER, D., PORT, J.D. & MÜLLER-BECKMANN, B. (1992). Receptor pharmacology of carvedilol in the human heart. J. Cardiovasc. Pharmacol., 19 (Suppl. 1): S68-S80.
10. 50) of an enzyme reaction. Biochem. Pharmacol., 22, 3099-3108.
11. 2-adrenergic receptor. Mol. Pharmacol., 50, 662-669.
12. CIBIS II INVESTIGATORS AND COMMITTEES. (1999). The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet. 353, 9-13.
13. DE LEAN, A., STADEL, J.M. & LEFKOWITZ, R.J. (1980). A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem., 255 , 7108-7117.
14. DEITCHMAN, D., PERHACH, J.L. & SNYDER, R.W. (1980). Beta-adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats. Eur. J. Pharmacol., 61, 263-277.
15. FREEMANTLE, N., CLELAND, J., YOUNG, P., MASON, J. & HARRISON, J. (1999). β-Blockade after myocardial infarction: systematic review and meta regression analysis. Brit. J. Med., 318, 1730-1737.
16. GILBERT, E.M., OLSEN, S.L., RENLUND, D.G. & BRISTOVV, M.R. (1993). Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am. J. Cardiol., 71, 23C-29C.
17. HASH, T.W. & PRISANT, L.M. (1997). β-Blocker use in systolic heart failure and dilated cardiomyopathy. J. Am. Coll. Cardiol., 37, 7-19.
18. HAUSDORFF, W.P., CARON, M.G. & LEFKOWITZ, R.J. (1990). Turning off the signal: Desensitization of β-adrenergic receptor function. FASEB J., 4, 2881-2889.
19. HEILBRUNN, S.M., SHAH, P., BRISTOW, M.R., VALANTINE, H.A., GINSBURG, R. & FOWLER, M.B. (1989). Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation, 79, 483-490.
20. HERSHBERGER, R.E., WYNN, J.R., SUNDBERG, L. & BRISTOW, M.R. (1990). Mechanisms of action of bucindolol in human ventricular myocardium. J. Cardiovasc. Pharmacol., 15, 959-967.
21. JASPER, R.J., MICHEL, M.C. & INSEL, P.A. (1988). Molecular mechanism of β-adrenergic receptor blockers with intrinsic sympathomimetic activity. FASEB J., 2, 2891-2894.
22. 1-adrenoceptor. FEBS Letts., 457, 302-306.
23. LOWRY, O.H., ROSENBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurements with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
24. MARWOOD, J.F. & STOKES, G.S. (1986). Studies on the vasodilator actions of bucindolol in the rat. Clin. Exper. Pharmacol. Physiol., 13, 59-68.
25. MERIT-HF STUDY GROUP. (1999). Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 353, 2001-2007.
26. MEWES, T., DUTZ, S., RAVENS, U. & JAKOBS, K.H. (1993). Activation of calcium currents in cardiac myocytes by empty beta-adrenoceptors. Circulation, 88, 2916-2922.
27. NICHOLAS, G., OAKLEY, C., POULEUR, H., ROUSSEAU, M.F., RYDEN, L.E. & WELLENS, H. for The Xamoterol In Heart Failure Study Group. (1990). Xamoterol in severe heart failure. Lancet, 336, 1-6.
28. PACKER, M., BRISTOW, M.R., COHN, J.N., COLUCCI, W., FOWLER, M.B., GILBERT, E.M. & SHUSTERMAN N.H., for the US Carvedilol Heart Failure Study Group. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med., 334, 1349-1355.
29. 2-adrenergic receptor. J. Biol. Chem., 268, 4625-4636.
30. SCATCHARD, G. (1949). The attractions of proteins for small molecules and ions. Ann. N. Y. Acad. Sci., 51, 660-672.
31. SORIANO, J.B., HOES, A.W., MEEMS, L. & GROBBEE, D.E. (1997). Increased survival with β-blockers: importance of ancillary properties. Progress in Cardiovascular Diseases, 39, 445-456.
32. TROCHU, J.N., ERFANIAN, M., KHANDOUDI, N., BARON. O., BRIL, A. & GAUTHIER, C. (1999). Carvedilol produces contractile effects different from those of bucindolol in human atria. Circulation, 100, 1-439 (abstract).
33. WILLETTE, R.N , MITCHELL, M.P., OHLSTEIN, E.H., LUKAS, M.A. & RUFFOLO, JR R.R.. (1998). Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart. Pharmacology, 56, 30-36.
34. YOSHIKAWA, T., PORT, J.D., ASANO, K., CHIDIAC, P., BOUVIER. M., DUTCHER, D., RODEN, R.L., MINOBE, W., TREMMEL, K D. & BRISTOW, M.R. (1996). Cardiac adrenergic receptor effects of carvedilol. Eur. Heart. J., 17 (Suppl. B): 8-16.